The main one was the use of dendritic cells (DCs, specific tumor antigen presentation) via an introduction of a granulocyte-macrophage colony stimulating factor (GMCSF)-CAIX fusion protein (produced by viral bioengineering), in order to activate DCs and thus trigger a CD8+ mediated, CAIX targeted, antitumoral response. This evidence concerns the gene CSF2 and neoplasm.